John Aballi

John Aballi has served as President and CEO as well as on the board of directors since October 2022. He most recently served as SVP, GM, Urology and CLIA COO for Veracyte, a San Francisco-based molecular diagnostic company. In this role, he maintained P&L responsibility for the business unit, ultimately expanding the urology franchise to $120 million-plus in annual revenue while maintaining responsibility for the company’s market access, billing and customer service functions in addition to Veracyte’s four US-based CLIA laboratories. Prior to this role, Mr. Aballi was a key member of the leadership team which transformed Decipher Biosciences to the market leader in genomic testing for prostate cancer. Decipher Biosciences was sold to Veracyte in March 2021 for $600 million and Mr. Aballi served as the SVP & Chief Operating Officer at the company, responsible for all aspects of operations including sales, quality management, medical operations, customer service, software development, assay development, billing, managed care, and laboratory operations; he assumed this role in August 2018. Mr. Aballi previously served as the Head of Operations at Molecular Stethoscope, a company developing cell-free RNA-based diagnostics, from September 2015 to August 2018.

Prior to joining Molecular Stethoscope, Mr. Aballi served in various senior roles at Genoptix from January 2007 to September 2015. Mr. Aballi was a Board Member of PFS Genomics in San Diego, a molecular diagnostic company specializing in proprietary signature development in breast cancer, which was acquired by Exact Sciences in 2021.

He holds an MBA from California Baptist University and dual degrees from UC San Diego in biochemistry and cell biology and economics.